Oncosil Medical Ltd has released a press release.
FDA Grants Breakthrough Device Designation
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from OncoSil Medical
- CE Mark Update
- Positive CE Mark Status Report
- OncoSil AGM CEO Presentation
- Receipt of $3.8M R&D Tax Incentive
- Appendix 4E and Full Year Statutory Accounts
Later from OncoSil Medical
- Pause in Trading
- Clarification Statement
- Oncosil breakthrough device receives CE Marking approval
- Proposed issue of Securities - OSL
- Allotment of Securities under Institutional Placement
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical